Health

At Week 52, Taltz and Zepbound maintained or further improved psoriasis or psoriatic arthritis disease activity from Week…

ROCHESTER — Mayo Clinic has issued its guidance for who should get the updated COVID-19 vaccine this fall.…

Accurately tracking what you eat is notoriously difficult. Still, the rapid rise of AI-powered apps that could simplify…

Remotely delivered exercise-based cardiac rehabilitation, when added to center-based programs, resulted in a similar number of completed sessions…

For breast cancer survivors, new research shows that feelings of depression and perceptions of psychological stress make the…

China’s efforts to embed artificial intelligence across industries, which it calls its “AI+ plan,” has generated plenty of…

Clinical trials of upadacitinib showed up to 23 percent of severe alopecia areata patients achieved complete scalp hair…

Get Rhode Map A weekday briefing from veteran Rhode Island reporters, focused on the things that matter most…

Women face numerous challenges as they move forward in their personal and professional lives. In order to overcome…

The quest for longevity is leaving some in worse shape than when they started. The FDA has issued…

8 min read A decade ago Megan Hill, a publicist in Los Angeles, was a member of a…

Men with prostate cancer have a high risk of heart disease, especially when treated with hormone therapy. A…

New Phase 3b data on Lilly’s Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity